Abstract: Systems, methods, and computer-program products for fluid analysis and monitoring are disclosed. Embodiments include a removable and replaceable sampling system and an analytical system connected to the sampling system. A fluid may be routed through the sampling system and data may be collected from the fluid via the sampling system. The sampling system may process and transmit the data to the analytical system. The analytical system may include a command and control system to receive and store the data in a database and compare the data to existing data for the fluid in the database to identify conditions in the fluid. Fluid conditions may be determined using machine learning models that are generated from well-characterized known training data. Predicted fluid conditions may then be used to automatically implement control processes for an operating machine containing the fluid.

Abstract: The present invention relates to a method for direct detection and differentiation of carbapenem-resistant bacteria in a sample comprising (i) inoculation with said sample of a culture medium comprising at least meropenem and/or ertapenem and at least one chromogenic agent, (ii) incubation of said culture medium under conditions allowing the growth of carbapenem-resistant bacteria, and (iii) detection of colonies formed on said culture medium corresponding to a carbapenem-resistant bacteria, as well as a culture medium suitable for use in such a method.

Abstract: A transaminase and a use thereof are provided. The transaminase has the amino acid sequences as shown in SEQ ID NO: 2 or 4, or has at least 80% identity to the amino acid sequences as shown in SEQ ID NO: 2 or 4, or has amino acid sequences which are obtained by the substitution, deletion or addition of one or more amino acids and have an the activity of an omega-transaminase with high stereoselective R-configuration catalytic activity, wherein the high stereoselective refers to the content of one of the stereoisomers being at least about 1.1 times that of the other.

Abstract: A method for detecting at least one microorganism present in a sample, that includes: a) in a first container, bringing the sample into contact with at least one culture medium, b) placing the first container in suitable conditions to permit growth of the microorganism or microorganisms, c) bringing some or all of the mixture being made of the sample and the culture medium into contact with a reaction mixture and a substrate for capturing the microorganism(s) in the first container or in a second container, the reaction mixture having a device for detecting the microorganism(s); d) detecting, within the first or second container, the presence of the microorganism or microorganisms detected by the detecting device and fixed on the capture substrate.

Abstract: The invention provides a method for screening for colorectal cancer, the method comprising: screening a biological sample from an individual for one or more biomarkers selected from the group defined in Table 1 and/or Table 6, wherein the presence of or increased expression of the one or more biomarkers relative to a control sample is indicative that the individual is at risk of suffering from or is suffering from colorectal cancer. The invention also provides an array and kit suitable for use in the methods of the invention, methods of treating colorectal cancer and therapeutic agents for use in methods of treating cancer.

Abstract: The invention relates to a device and a method for measuring neurotransmitters in the brain dialysate of mammals using enzymatic reactors specific to a certain neurotransmitter, which generate fluorescent derivatives when mixed. The mixture is introduced into an incubation chamber and passes through a temperature controlling system in order to set it to the optimum enzymatic reaction temperature, and the fluorescent derivative generated is passed through a flow fluorescence cell located inside the incubation chamber, where the liquid is impacted with a laser light source via an optical fibre. The fluorescence emitted is captured by a fluorescence detector that sends it to a processing system in order to obtain the corresponding values.

Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.

Abstract: The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of: (i) transforming mouse ES cells with a DNA fragment containing a liver-specific promoter/enhancer and cDNA that encodes a urokinase-type plasminogen activator operably linked under the control thereof; (ii) injecting the transformed mouse ES cells obtained in step (i) into a host embryo; (iii) transplanting the host embryo obtained in step (ii) via the injection of the ES cells into the uterus of a surrogate mother mouse, so as to obtain a chimeric mouse; and (iv) crossing the chimeric mice obtained in step (iii), so as to obtain a transgenic mouse in which the DNA fragment is introduced in a heterozygous form.

Abstract: A method of determining hypoxia in fetal scalp blood sampled during labor including the determination of total lactate dehydrogenase (LDH) in plasma obtained from the sample. The method can include the additional determination of K, Mg, Ca, AST, ALT, lactate in the plasma and/or blood. Increased values of one or more of LDH, Mg, Ca, AST, ALT, lactate are indicative of hypoxia in the fetus. Also disclosed is the use of a plasma separation apparatus in the method.

Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.

Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.

Abstract: This invention relates to a testing system for assessing the level of a biochemical marker, comprising a disposable device (2) with a sample inlet (4) and a at least one visible detection compartment (5A, 5B), arranged with composition including a chemical means (Y) for direct detection of said biochemical marker, wherein said composition also includes an inhibitor (Z) arranged to first detection compartment (5A) being arranged to block the biochemical marker up to a certain concentration.

Abstract: An analytical apparatus is disclosed for detecting at least one analyte in a sample, where in an analyte measurement at least an electrical or optical property changeable by presence of the analyte at least one test chemical of a test element is recorded, and where the analytical apparatus also can perform at least one quality measurement on the at least one test chemical such as an intrinsic luminescence, which is recorded and from the intrinsic luminescence a conclusion is drawn on a quality of the test chemical and thus the test element. Methods also are disclosed for detecting at least one analyte in a sample that include a quality measurement of the at least one test chemical of the test strip.

Abstract: Use of photochemically cleavable compounds in course of one or multi-photon irradiation experiments.

Abstract: The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods.

Abstract: The present invention relates to a method for early evaluation of clinical efficacy of antitumor intervention measure, comprising evaluating the efficacy of the antitumor intervention measure by assaying whether the content of a tumor-damaging biomarker(s) in the blood of a patient having tumor rises as compared to the baseline level before treatment within a time window after the patients receives at least one antitumor intervention measure. In preferable embodiments, the tumor-damaging biomarker(s) is selected from a group consisting of Alanine Aminotransferase (ALT), Aspartate Transaminase (AST), Lactate Dehydrogenase (LDH); said tumor is multiple myeloma; said antitumor intervention measure is the administration of CPT alone or the administration of CPT in combination with thalidomide.

Abstract: The present invention relates to the production of optically active amines, which can be used as intermediate products in a synthesis of for instance pharmaceutical products.

Abstract: The present invention relates to processes for the screening, preparation and characterization of (R)-selective ?-transaminases, to transaminases obtained thereby and their uses in various transamination processes.

Abstract: The invention relates to a sensor comprising a sensing layer and a surface layer, wherein said surface layer comprises, a first region suitable for adherent growth of cells, and a second region, adjacent to said second layer, suitable for the attachment of proteins, wherein the first and second region are in contact with the sensing layer.

Abstract: Ratios of measured values of glucose, citrate, and cis-aconitate in a biological sample obtained from a subject to measured values of glucose, citrate, and cis-aconitate in a biological sample obtained from a healthy subject are calculated, and the glucose ratio, the citrate ratio, and the cis-aconitate ratio are used to evaluate and/or assess fatigue. Similarly, an isocitrate ratio, a succinate ratio, a malate ratio, and a lactate ratio are calculated, and these ratios are used together with the three ratios to evaluate and/or assess fatigue. This makes it possible to objectively and easily diagnose and evaluate fatigue.

Abstract: The invention is directed to a treatment of diseases that are accompanied by quantitative and/or qualitative changes of blood extracellular DNA and, more particularly, to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method comprises introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa, wherein said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNase enzyme: said agent being administered in doses and regimens which are sufficient to decrease the average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease in the average molecular weight can be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient.

Abstract: The detection of a non-alcoholic steatohepatitis patient and the accurate discrimination between a normal person and a non-alcoholic steatohepatitis patient can be achieved by measuring alanine-glyoxylate amino transferase in a sample.

Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.

Abstract: A treatment for systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA and, more particularly, to a treatment of diabetes mellitus and atherosclerosis. The inventive method consist from introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic DNA mutation diseases when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme: said agent might be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease of number average molecular weight might be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient.

Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.

Abstract: A method for the prevention or treatment of a condition selected from type 2 diabetes, obesity and metabolic syndrome comprising activating a GITRL pathway. Methods for screening for substances to treat these conditions, diagnosing or predicting these conditions and selecting and monitoring therapies.

Abstract: Provided is a processing apparatus for enabling a plurality of processes to be conducted on a sample within a microfluidic or nanofluidic cartridge, the apparatus comprising: a) a plurality of processing modules for facilitating the processes conducted on the sample within the cartridge; b) a coupling means for reversibly coupling the cartridge to the apparatus; c) a transport means capable of bringing the cartridge coupled to the coupling means into communication with each of the processing modules; wherein the plurality of processing modules includes a component isolation module capable of facilitating a separation process within the cartridge, a manipulator module capable of facilitating the movement of fluids within the cartridge; and an optical module capable of interacting optically with the cartridge.

Abstract: Engineered human tissue constructs are provided that are suitable for use in making humanized animals for use in pharmaceutical development. Humanized animals having the constructs implanted in vivo are provided. Methods of making and using the tissue-engineered constructs and humanized animals are also provided.

Abstract: Systems and methods are provided for monitoring a immunosuppressant drug level and renal function, hepatic function, or a combination thereof in a patient, comprising obtaining a small volume blood sample from the patient; determining the level of at least one immunosuppressant drug in the small volume blood sample and determining the level of a second immunosuppressant drug or analyzing the renal function, the hepatic function, or a combination thereof in the patient. In some embodiments, the immunosuppressant drug levels are determined using a liquid chromatography tandem mass spectrometry (LC-MS/MS) procedure. Also provided are kits for use in any of the systems and methods described herein.

Abstract: Disclosed herein is a novel use of glucosamine or a derivative thereof. A pharmaceutical composition for treating atopic dermatitis comprising glucosamine or a derivative thereof and a method of treating atopic dermatitis using the composition are disclosed. The pharmaceutical composition and the method realize the safe treatment of atopic dermatitis without the side effects associated with conventional anti-inflammatory drugs.

Abstract: The present invention relates to processes for the screening, preparation and characterization of (R)-selective ?-transaminases, to transaminases obtained thereby and their uses in various transamination processes.

Abstract: Methods and compositions relating to CDP-taxane conjugates are described herein.

Abstract: An in-vitro non-invasive method for quantifying the lesions of the liver of the patient with metabolic steatosis addressing a diagnostic target, i.e. fibrosis, steatosis and/or steato-hepatitis (NASH) and measuring at least one marker selected from the group consisting of biomarkers and possibly clinical markers and possibly scores, the biomarkers being selected from the group consisting of glycemia, AST (aspartate aminotransferase), ALT (alanine aminotransferase), AST/ALT, AST.

Abstract: Provided herein are methods for the diagnosis, staging, prognosis, or management of liver disease, e.g. chronic liver disease, and other diseases using profiles of the ubiquitin-proteasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of patients with liver disease.

Abstract: Methods and compositions relating to CDP-taxane conjugates are described herein.

Abstract: The present invention relates a detecting method of distinguishing a temporary liver function test abnormalities by a thyrotoxicosis from a drug-induced hepatic injury by an antithyroid drug using a blood test and the likes, which is performed in a simple manner and with specificity. In the course of treating Graves' disease using an antithyroid drug, it is possible to differentiate a temporary liver function test abnormalities resulted from a thyrotoxicosis from a drug-induced hepatic injury resulted from the antithyroid drug, and therefore to detect the drug-induced hepatic injury with specificity by assaying a level of OCT in a body sample from a patient. In other words, it is possible to diagnose as a drug-induced hepatic injury if a blood OCT level in the sample from the patient is elevated compared to a level prior to administering the antithyroid drug or a blood OCT level from normal persons.

Abstract: Human GFAT genes are identified as modulators of the Axin pathway, and thus are therapeutic targets for disorders associated with defective Axin function. Methods for identifying modulators of Axin, comprising screening for agents that modulate the activity of GFAT are provided.

Abstract: Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided.

Abstract: In certain embodiments, the present invention provides oligomeric compounds having favorable toxicity profiles and therapeutic indexes. Compounds of the present invention comprise bicyclic nucleosides. Certain such bicyclic nucleosides are pyrimidines that do not include a methyl group at the 5-carbon. Oligomeric compounds comprising such nucleosides are less toxic than compounds comprising bicyclic nucleosides that do include a methyl group at the 5-carbon. In certain embodiments, the present invention provides methods of preparing and using such compounds.

Abstract: Disclosed herein is a dry fluorescence biosensor strip for rapid detection of a target analyte present in bodily fluids. The dry fluorescence biosensor strip comprises a sample receptacle and a dry detection membrane. The sample receptacle receives a sample of one of the bodily fluids. The dry detection membrane detects presence of the target analyte in the received sample based on fluorescence induced on the dry detection membrane. Fluorescent signals are emitted from the dry detection membrane on induction of fluorescence. A fluorometer quantifies measurable properties of the target analyte based on the emitted fluorescent signals. The dry fluorescence biosensor strip may further comprise a filtration membrane for filtering the received sample. The filtered sample migrates from the filtration membrane to the dry detection membrane. The dry detection membrane may then detect presence of the target analyte in the filtered sample.

Abstract: The invention relates to a method of determination of alanine transaminase (ALT) activity by 13C-MR detection using an imaging medium which comprises hyperpolarised 13C-pyruvate.

Abstract: The invention relates to a sensor (1) comprising a sensing layer (2) and a surface layer (3), wherein said surface layer comprises, a first region (4) suitable for adherent growth of cells (6), and a second region (5), adjacent to said second layer, suitable for the attachment of proteins, wherein the first and second region are in contact with the sensing layer.

Abstract: The present invention provides assays for detecting ADP, GDP and inorganic phosphate. These assays can be used directly to detect the presence of ADP, GDP and inorganic phosphate or can be used as part of a number of methods for identifying candidate agents that bind to a target protein or serve as modulators of the biological activity of a target protein.

Abstract: The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin, Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.

Abstract: Tissue transglutaminase-2 (TG2) is involved in Ca++-dependent aggregation and polymerization of proteins. TG2 is upregulated in epithelial ovarian cancer (EOC) cells as compared to normal ovarian epithelium. TG2 is also highly expressed in ovarian tumors and secreted in malignant ascites, but it is not detected in non-transformed ovarian epithelium. Furthermore, TG2 enhances EOC cell adhesion to fibronectin and haptotactic cell migration. This phenotype is preserved in-vivo, where the pattern of tumor dissemination in the peritoneal space is dependent on TG2 expression levels. TG2 knock down diminishes dissemination of tumors on the peritoneal surface and mesentery in an i.p. ovarian xenograft model. This phenotype is due to deficient ?1 integrin-fibronectin interaction, leading to weaker anchorage of cancer cells to the peritoneal matrix.

Abstract: Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and ?-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.

Abstract: The present invention relates to a method of measuring the activity of a kynurenine-converting enzyme and/or a kynurenic-acid-, anthranilic-acid- and/or 3-hydroxykynurenine-producing enzyme, the method comprising the step of measuring the activity in the presence of an interfering sample, preferably selected from a CSF (cerebrospinal fluid) or serum, and detecting the conversion of kynurenine and/or kynurenic acid and/or anthranilic acid and/or 3-hydroxykynurenine.

Abstract: Systems and methods are provided for monitoring a immunosuppressant drug level and renal function, hepatic function, or a combination thereof in a patient, comprising obtaining a small volume blood sample from the patient; determining the level of at least one immunosuppressant drug in the small volume blood sample and determining the level of a second immunosuppressant drug or analyzing the renal function, the hepatic function, or a combination thereof in the patient. In some embodiments, the immunosuppressant drug levels are determined using a liquid chromatography tandem mass spectrometry (LC-MS/MS) procedure. Also provided are kits for use in any of the systems and methods described herein.

Abstract: By means of a proteomic approach, the markers of hepatocellular carcinoma (HCC) in the liver of a knockout mouse (MAT1A?/?) have been identified for the MAT1A gene (deficient in the synthesis of S-adenosylmethionine). 27 proteins have been detected the expression thereof is altered in, at least, 50% of the analysed tumours. Amongst them, 13 proteins have been validated in biopsies of patients with HCC of different etiology, and 7 of them have been validated in biopsies of patients with liver cirrhosis, a stage prior to the development of HCC, which makes it possible to differentiate between prior stages of the disease and even between different etiologies (viral and alcoholic). Having a panel of markers available may contribute to more accurately defining the alterations associated with the development of HCC and thus facilitate prognosis and diagnosis of this disease.

Abstract: This invention provides a method for differentially and simultaneously quantifying two target analytes via a single assay operation with the use of a single type of reagent in each of the two steps, i.e., the first step and the second step. In this method, the reaction product associated with the first target analyte is detected at an early stage of the second step and the reaction product associated with the second target analyte is then detected.